Phio Pharmaceuticals Corp.
PHIO
$1.98
-$0.16-7.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -2.18% | -64.38% | -- | -46.20% | -37.61% |
| Gross Profit | 2.18% | 64.38% | -- | 46.20% | 37.61% |
| SG&A Expenses | -10.05% | -2.27% | -9.97% | -27.72% | -31.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.58% | -42.72% | -24.85% | -38.67% | -35.05% |
| Operating Income | 5.58% | 42.72% | 24.85% | 38.67% | 35.05% |
| Income Before Tax | 14.20% | 45.18% | 27.58% | 40.20% | 30.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.20% | 45.18% | 27.58% | 40.20% | 30.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.20% | 45.18% | 27.58% | 40.20% | 30.61% |
| EBIT | 5.58% | 42.72% | 24.85% | 38.67% | 35.05% |
| EBITDA | 5.05% | 42.41% | 24.45% | 38.43% | 35.06% |
| EPS Basic | 74.77% | 84.99% | 72.74% | 85.09% | 73.74% |
| Normalized Basic EPS | 72.98% | 84.99% | 72.74% | 85.09% | 75.48% |
| EPS Diluted | 74.77% | 84.99% | 72.73% | 85.09% | 73.77% |
| Normalized Diluted EPS | 72.98% | 84.99% | 72.74% | 85.09% | 75.48% |
| Average Basic Shares Outstanding | 240.07% | 265.18% | 165.59% | 301.02% | 164.14% |
| Average Diluted Shares Outstanding | 240.07% | 265.18% | 165.59% | 301.02% | 164.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |